Effects of vitamin K1 supplements on the INR and vitamin K-dependent proteins after OAC treatment
Dose and day . | INR, % . | FIIc, % . | FVIIc, % . | ucFII, AU/L × 103 . | ucOC, ng/mL . | cOC, ng/mL . |
|---|---|---|---|---|---|---|
| 0 μg/day | ||||||
| Mon | 2.04 ± 0.31 | 46.3 ± 9.0 | 52.7 ± 23.5 | 24.4 ± 6.4 | 31.5 ± 8.1 | 2.2 ± 0.9 |
| Tue | 2.08 ± 0.38 | 45.7 ± 10.8 | 47.8 ± 23.0 | 23.6 ± 8.9 | 33.1 ± 9.2 | 2.1 ± 0.8 |
| Wed | 2.02 ± 0.41 | — | — | — | — | — |
| Fri | 2.04 ± 0.50 | — | — | |||
| Mon | 1.93 ± 0.26 | 45.7 ± 7.1 | 49.4 ± 16.6 | 26.9 ± 10.4 | 29.9 ± 8.8 | 2.1 ± 0.5 |
| 50 μg/day | ||||||
| Tue | 1.95 ± 0.36 | 51.8 ± 10.6 | 58.6 ± 36.1 | 27.3 ± 14.0 | 32.4 ± 8.8 | 2.1 ± 0.8 |
| Wed | 1.81 ± 0.29 | — | — | — | — | — |
| Fri | 1.73 ± 0.27 | — | — | — | — | — |
| Mon | 1.85 ± 0.31 | 50.0 ± 8.4 | 50.3 ± 23.6 | 22.4 ± 17.9 | 30.6 ± 9.9 | 2.0 ± 0.9 |
| 100 μg/day | ||||||
| Tue | 1.86 ± 0.30 | 52.8 ± 7.0 | 54.7 ± 20.1 | 19.1 ± 9.2* | 33.4 ± 9.1 | 2.0 ± 1.1 |
| Wed | 1.78 ± 0.29 | — | — | — | — | — |
| Fri | 1.67 ± 0.22 | — | — | — | — | — |
| Mon | 1.75 ± 0.26 | 48.3 ± 17.2 | 44.3 ± 17.2 | 20.5 ± 11.8 | 33.0 ± 8.2 | 2.4 ± 1.6 |
| 150 μg/day | ||||||
| Tue | 1.75 ± 0.24 | 55.1 ± 8.7 | 62.8 ± 25.3 | 19.2 ± 8.2 | 32.6 ± 7.8 | 2.7 ± 1.2 |
| Wed | 1.59 ± 0.26* | — | — | — | — | — |
| Fri | 1.56 ± 0.27 | — | — | — | — | — |
| Mon | 1.58 ± 0.20 | 55.0 ± 8.0* | 66.4 ± 43.5 | 15.1 ± 8.2 | 31.0 ± 9.2 | 2.4 ± 1.1 |
| 200 μg/day | ||||||
| Tue | 1.57 ± 0.23 | 56.7 ± 8.8 | 69.3 ± 26.7 | 15.4 ± 9.6 | 32.3 ± 6.2 | 2.9 ± 1.1 |
| Wed | 1.54 ± 0.16 | — | — | — | — | — |
| Fri | 1.50 ± 0.21 | — | — | — | — | — |
| Mon | 1.53 ± 0.18 | 59.3 ± 7.5 | 61.9 ± 19.4* | 16.3 ± 9.8 | 32.7 ± 8.2 | 3.1 ± 1.4 |
| 250 μg/day | ||||||
| Tue | 1.55 ± 0.24 | 61.1 ± 5.2 | 69.4 ± 19.2 | 12.1 ± 5.9 | 29.8 ± 8.5 | 3.0 ± 1.0* |
| Wed | 1.50 ± 0.15 | — | — | — | — | — |
| Fri | 1.53 ± 0.16 | — | — | — | — | — |
| Mon | 1.47 ± 0.24 | 61.9 ± 6.7 | 75.8 ± 39.1 | 14.3 ± 8.2 | 27.9 ± 9.9 | 2.9 ± 1.6 |
| 300 μg/day | ||||||
| Tue | 1.47 ± 0.15 | 57.9 ± 5.6 | 61.3 ± 29.9 | 10.4 ± 6.5 | 20.8 ± 8.1 | 3.6 ± 1.6 |
| Wed | 1.51 ± 0.13 | — | — | — | — | — |
| Fri | 1.57 ± 0.11 | — | — | — | — | — |
| Mon | 1.42 ± 0.17 | 64.5 ± 9.5 | 75.4 ± 30.1 | 9.4 ± 10.3 | 19.2 ± 4.3* | 4.3 ± 1.2 |
| 500 μg/day | ||||||
| Tue | 1.39 ± 0.13 | 64.0 ± 6.9 | 60.3 ± 12.0 | 6.1 ± 4.0 | 18.5 ± 5.4 | 4.4 ± 1.2 |
| Wed | 1.41 ± 0.14 | — | — | — | — | — |
| Fri | 1.37 ± 0.12 | — | — | — | — | — |
Dose and day . | INR, % . | FIIc, % . | FVIIc, % . | ucFII, AU/L × 103 . | ucOC, ng/mL . | cOC, ng/mL . |
|---|---|---|---|---|---|---|
| 0 μg/day | ||||||
| Mon | 2.04 ± 0.31 | 46.3 ± 9.0 | 52.7 ± 23.5 | 24.4 ± 6.4 | 31.5 ± 8.1 | 2.2 ± 0.9 |
| Tue | 2.08 ± 0.38 | 45.7 ± 10.8 | 47.8 ± 23.0 | 23.6 ± 8.9 | 33.1 ± 9.2 | 2.1 ± 0.8 |
| Wed | 2.02 ± 0.41 | — | — | — | — | — |
| Fri | 2.04 ± 0.50 | — | — | |||
| Mon | 1.93 ± 0.26 | 45.7 ± 7.1 | 49.4 ± 16.6 | 26.9 ± 10.4 | 29.9 ± 8.8 | 2.1 ± 0.5 |
| 50 μg/day | ||||||
| Tue | 1.95 ± 0.36 | 51.8 ± 10.6 | 58.6 ± 36.1 | 27.3 ± 14.0 | 32.4 ± 8.8 | 2.1 ± 0.8 |
| Wed | 1.81 ± 0.29 | — | — | — | — | — |
| Fri | 1.73 ± 0.27 | — | — | — | — | — |
| Mon | 1.85 ± 0.31 | 50.0 ± 8.4 | 50.3 ± 23.6 | 22.4 ± 17.9 | 30.6 ± 9.9 | 2.0 ± 0.9 |
| 100 μg/day | ||||||
| Tue | 1.86 ± 0.30 | 52.8 ± 7.0 | 54.7 ± 20.1 | 19.1 ± 9.2* | 33.4 ± 9.1 | 2.0 ± 1.1 |
| Wed | 1.78 ± 0.29 | — | — | — | — | — |
| Fri | 1.67 ± 0.22 | — | — | — | — | — |
| Mon | 1.75 ± 0.26 | 48.3 ± 17.2 | 44.3 ± 17.2 | 20.5 ± 11.8 | 33.0 ± 8.2 | 2.4 ± 1.6 |
| 150 μg/day | ||||||
| Tue | 1.75 ± 0.24 | 55.1 ± 8.7 | 62.8 ± 25.3 | 19.2 ± 8.2 | 32.6 ± 7.8 | 2.7 ± 1.2 |
| Wed | 1.59 ± 0.26* | — | — | — | — | — |
| Fri | 1.56 ± 0.27 | — | — | — | — | — |
| Mon | 1.58 ± 0.20 | 55.0 ± 8.0* | 66.4 ± 43.5 | 15.1 ± 8.2 | 31.0 ± 9.2 | 2.4 ± 1.1 |
| 200 μg/day | ||||||
| Tue | 1.57 ± 0.23 | 56.7 ± 8.8 | 69.3 ± 26.7 | 15.4 ± 9.6 | 32.3 ± 6.2 | 2.9 ± 1.1 |
| Wed | 1.54 ± 0.16 | — | — | — | — | — |
| Fri | 1.50 ± 0.21 | — | — | — | — | — |
| Mon | 1.53 ± 0.18 | 59.3 ± 7.5 | 61.9 ± 19.4* | 16.3 ± 9.8 | 32.7 ± 8.2 | 3.1 ± 1.4 |
| 250 μg/day | ||||||
| Tue | 1.55 ± 0.24 | 61.1 ± 5.2 | 69.4 ± 19.2 | 12.1 ± 5.9 | 29.8 ± 8.5 | 3.0 ± 1.0* |
| Wed | 1.50 ± 0.15 | — | — | — | — | — |
| Fri | 1.53 ± 0.16 | — | — | — | — | — |
| Mon | 1.47 ± 0.24 | 61.9 ± 6.7 | 75.8 ± 39.1 | 14.3 ± 8.2 | 27.9 ± 9.9 | 2.9 ± 1.6 |
| 300 μg/day | ||||||
| Tue | 1.47 ± 0.15 | 57.9 ± 5.6 | 61.3 ± 29.9 | 10.4 ± 6.5 | 20.8 ± 8.1 | 3.6 ± 1.6 |
| Wed | 1.51 ± 0.13 | — | — | — | — | — |
| Fri | 1.57 ± 0.11 | — | — | — | — | — |
| Mon | 1.42 ± 0.17 | 64.5 ± 9.5 | 75.4 ± 30.1 | 9.4 ± 10.3 | 19.2 ± 4.3* | 4.3 ± 1.2 |
| 500 μg/day | ||||||
| Tue | 1.39 ± 0.13 | 64.0 ± 6.9 | 60.3 ± 12.0 | 6.1 ± 4.0 | 18.5 ± 5.4 | 4.4 ± 1.2 |
| Wed | 1.41 ± 0.14 | — | — | — | — | — |
| Fri | 1.37 ± 0.12 | — | — | — | — | — |
Mena group values are given ± the standard deviation for 12 volunteers. The first point (t = 0) of each new dose was identical to the last point (t = 7 days) of the previous dose. — indicates not determined.
Indicates dose and day on which the group value (n = 12) for each measurement first became significantly (P < .05) different from the baseline (presupplementation, 0 μg/day) value. See the text (“Study phase I : daily supplementation with synthetic vitamin K”) for differences between men and women.